These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 23759796)

  • 1. Is mipomersen ready for clinical implementation? A transatlantic dilemma.
    Sjouke B; Balak DM; Beuers U; Ratziu V; Stroes ES
    Curr Opin Lipidol; 2013 Aug; 24(4):301-6. PubMed ID: 23759796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mipomersen as a potential adjunctive therapy for hypercholesterolemia.
    Patel N; Hegele RA
    Expert Opin Pharmacother; 2010 Oct; 11(15):2569-72. PubMed ID: 20707601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of mipomersen sodium (Kynamro).
    Hovingh K; Besseling J; Kastelein J
    Expert Opin Drug Saf; 2013 Jul; 12(4):569-79. PubMed ID: 23611600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial.
    Raal FJ; Santos RD; Blom DJ; Marais AD; Charng MJ; Cromwell WC; Lachmann RH; Gaudet D; Tan JL; Chasan-Taber S; Tribble DL; Flaim JD; Crooke ST
    Lancet; 2010 Mar; 375(9719):998-1006. PubMed ID: 20227758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease.
    Stein EA; Dufour R; Gagne C; Gaudet D; East C; Donovan JM; Chin W; Tribble DL; McGowan M
    Circulation; 2012 Nov; 126(19):2283-92. PubMed ID: 23060426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mipomersen and other therapies for the treatment of severe familial hypercholesterolemia.
    Bell DA; Hooper AJ; Watts GF; Burnett JR
    Vasc Health Risk Manag; 2012; 8():651-9. PubMed ID: 23226021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lomitapide and mipomersen: novel lipid-lowering agents for the management of familial hypercholesterolemia.
    Dixon DL; Sisson EM; Butler M; Higbea A; Muoio B; Turner B
    J Cardiovasc Nurs; 2014; 29(5):E7-E12. PubMed ID: 24231894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic potential of mipomersen in the management of familial hypercholesterolaemia.
    Gelsinger C; Steinhagen-Thiessen E; Kassner U
    Drugs; 2012 Jul; 72(11):1445-55. PubMed ID: 22799743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pediatric experience with mipomersen as adjunctive therapy for homozygous familial hypercholesterolemia.
    Raal FJ; Braamskamp MJ; Selvey SL; Sensinger CH; Kastelein JJ
    J Clin Lipidol; 2016; 10(4):860-869. PubMed ID: 27578117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The potential of mipomersen, an ApoB synthesis inhibitor, to reduce necessity for LDL-apheresis in patients with heterozygous familial hypercholesterolemia and coronary artery disease.
    Vogt A; Parhofer KG
    Expert Opin Pharmacother; 2013 Apr; 14(6):691-7. PubMed ID: 23477485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia.
    Rader DJ; Kastelein JJ
    Circulation; 2014 Mar; 129(9):1022-32. PubMed ID: 24589695
    [No Abstract]   [Full Text] [Related]  

  • 12. Mipomersen, an antisense apolipoprotein B synthesis inhibitor.
    Bell DA; Hooper AJ; Burnett JR
    Expert Opin Investig Drugs; 2011 Feb; 20(2):265-72. PubMed ID: 21210756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apolipoprotein B synthesis inhibition: results from clinical trials.
    Visser ME; Kastelein JJ; Stroes ES
    Curr Opin Lipidol; 2010 Aug; 21(4):319-23. PubMed ID: 20508521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mipomersen and lomitapide: Two new drugs for the treatment of homozygous familial hypercholesterolemia.
    Gouni-Berthold I; Berthold HK
    Atheroscler Suppl; 2015 May; 18():28-34. PubMed ID: 25936301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Balancing Low-density Lipoprotein Cholesterol Reduction and Hepatotoxicity With Lomitapide Mesylate and Mipomersen in Patients With Homozygous Familial Hypercholesterolemia.
    Won JI; Zhang J; Tecson KM; McCullough PA
    Rev Cardiovasc Med; 2017; 18(1):21-28. PubMed ID: 28509890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mipomersen: a safe and effective antisense therapy adjunct to statins in patients with hypercholesterolemia.
    Ricotta DN; Frishman W
    Cardiol Rev; 2012; 20(2):90-5. PubMed ID: 22293857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two new drugs for homozygous familial hyperchelesterolemia.
    Med Lett Drugs Ther; 2013 Apr; 55(1413):25-7. PubMed ID: 23545581
    [No Abstract]   [Full Text] [Related]  

  • 18. Effect of mipomersen on LDL-cholesterol in patients with severe LDL-hypercholesterolaemia and atherosclerosis treated by lipoprotein apheresis (The MICA-Study).
    Waldmann E; Vogt A; Crispin A; Altenhofer J; Riks I; Parhofer KG
    Atherosclerosis; 2017 Apr; 259():20-25. PubMed ID: 28279833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy.
    McGowan MP; Tardif JC; Ceska R; Burgess LJ; Soran H; Gouni-Berthold I; Wagener G; Chasan-Taber S
    PLoS One; 2012; 7(11):e49006. PubMed ID: 23152839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging LDL therapies: Mipomersen-antisense oligonucleotide therapy in the management of hypercholesterolemia.
    Toth PP
    J Clin Lipidol; 2013; 7(3 Suppl):S6-10. PubMed ID: 23642326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.